By crosslinking the transcriptomes of the MKRN1- and AGC1-deficient CRC cells, we identified that DEGs were primarily enriched in pathways related to mitochondrial dysfunction, antioxidant responses, and tumor drug resistance. This evidence concerns the gene SLC25A12 and neoplasm.